Description
Platelets play a critical role in the pathophysiology of acute coronary syndromes (ACS) and thromboembolic complications associated with atrial fibrillation. Anticoagulant and antiplatelet therapies are central to the treatment of ACS and atrial fibrillation. Over the last several decades, a better understanding of the pathogenesis of coronary heart disease and atrial fibrillation has led to refinements in antithrombotic strategies and clinical outcomes.With this in mind, some of the issues outlined in this book are new insights in genetic testing and modification of individualized antiplatelet therapy based on rapid bedside platelet analyzers. Most importantly, the current update of pros and cons of novel antiplatelet agents such as prasugrel and ticagrelor are provided in detail. Conventional antiplatelet strategies with aspirin and clopidogrel are also discussed. Special attention is devoted to experimental antiplatelet agents like PAR-1 thrombin receptor antagonists or aptamers.The ability to focus on different diseases beyond ACS, including heart failure and atrial fibrillation, distinguishes this publication. Each chapter was written by top experts in the field and scientists with the utmost authority and expertise to provide cardiologists, internists, and clinical pharmacologists with the latest updates.
Chapter
Impact of Antiplatelet Therapy in Heart Disease
Antiplatelet Therapy in Acute Coronary Syndrome and Atrial Fibrillation: Aspirin
Aspirin in Acute Coronary Syndrome
Clopidogrel in Coronary Artery Disease: Update 2012
Clopidogrel in Stable/Elective Patients Referred for Percutaneous Coronary Interventions
Clopidogrel in Non- ST-Segment Elevation Myocardial Infarction (NSTEMI)
Clopidogrel in ST-Segment Elevation Myocardial Infarction (STEMI)
Frequently Discussed Topics When Clopidogrel Is Used
Duration of Dual Antiplatelet Therapy
Prasugrel: Pharmacokinetics, Pharmacodynamics, and Drug Interactions
Prasugrel in High- Risk Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The TRITON- TIMI 38 Trial
Impact of Prasugrel on Early and Late Events
Prasugrel and Reduction of Ischemic Events: Myocardial Infarction and Stent Thrombosis
Specific Populations: ST-Elevation Myocardial Infarction, Diabetes, Vulnerable Patients, and Coronary Artery Bypass Grafting
Prasugrel: Ongoing Studies
Antiplatelet Therapy in Acute Coronary Syndromes: Ticagrelor
PLATO Baseline Characteristics and Randomized Treatment
PLATO Trial Results – Efficacy
PLATO Trial Results – Safety
Additional Ticagrelor Studies in Patients with Ischemic Heart Disease
Dipyridamole in Antithrombotic Treatment
Antithrombotic Rather than Antiplatelet Activity by Dipyridamole
The Importance of Sufficient Plasma Concentration
Protecting Tissue – Pleiotropic Effects
Inhibition of Thrombin Formation
Inhibition of Smooth Muscle Cell Proliferation – Prevention of Restenosis
Inhibiting Innate Inflammation
Protease-Activated Receptor-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Acute Coronary Syndrome
Rationale for Developing PAR-1 Inhibitors
Protease-Activated Receptor-1 Inhibitors in Advanced Clinical Development: Vorapaxar and Atopaxar
Ongoing Phase III of Vorapaxar
Clopidogrel: Metabolism and Mechanism of Action
CYP2C19 Genotype and Phenotype
CYP2C19 and Clopidogrel Pharmacokinetic and Pharmacodynamics
CYP2C19 and Cardiovascular Outcomes
CYP2C19 and Antiplatelet Therapy for Atrial Fibrillation
Other Genetic Polymorphisms
Alternative P2Y12 Antagonists and Clopidogrel Dosing Strategies
Clopidogrel Pharmacogenomics and Clinical Decision-Making
Stents and Antiplatelet Therapy
Choice of Antiplatelet Agents to Prevent Stent Thrombosis
Bleeding and the Use of Antiplatelet Agents in the Management of Acute Coronary Syndromes and Atrial Fibrillation
Definitions of Bleeding Used in Trials and Registries
Mechanisms Linking Bleeding to Mortality
Individual Antiplatelet Agents
Strategies to Reduce Bleeding Risk with Antiplatelet Agents
Antiplatelet Therapy in Stroke Prevention
Antiplatelet Therapy for Primary Prevention of Stroke
Antiplatelet Therapy for Secondary Prevention of Stroke
Stroke Prevention in Atrial Fibrillation
Challenges in Atrial Fibrillation
A Call to Engage in a Competition
A Claim That a Voter Is Unqualified
Demand for Explanation or Justification
A Sentry’s Call to an Unknown Party for Proper Identification
Antiplatelet Therapy in ACS and A-Fib
( Advances in Cardiology )
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
